E. Magnus Ohman
Duke University
Internal medicineSurgeryCardiologyRandomized controlled trialIntensive care medicineST segmentST elevationAcute coronary syndromeUnstable anginaHeart failureCoronary artery diseaseRevascularizationAngioplastyPercutaneous coronary interventionPopulationConventional PCIMyocardial infarctionStrokeClinical trialMedicine
Publications 697
#1Alexander E. Sullivan (VUMC: Vanderbilt University Medical Center)
#2Michael G. Nanna (Yale University)H-Index: 9
Last. Jennifer A. Rymer (Duke University)H-Index: 15
view all 13 authors...
Abstract Patients undergoing early surgery after coronary stent implantation are at increased risk for mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in pa...
#1Fabien PicardH-Index: 8
#2Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 167
Last. Philippe Gabriel StegH-Index: 96
view all 10 authors...
Abstract null null Background null The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial) trial demonstrated that high-dose icosapent-ethyl reduced the risk of ischemic events in statin-treated patients with elevated triglycerides (TG) and either atherosclerotic cardiovascular disease (ASCVD) or diabetes plus at least one risk factor. null null null Methods and results null Using data from REACH (Reduction of Atherothrombosis for Continued Health), a large int...
#1Bjorn Redfors (ISMMS: Icahn School of Medicine at Mount Sinai)
#2Matheus SimonatoH-Index: 13
Last. Akiko MaeharaH-Index: 60
view all 12 authors...
OBJECTIVES Incidence and prognosis of ST-segment elevation myocardial infarction (STEMI) vary according to ambient temperature and season. We sought to assess whether season and temperature on the day of STEMI are associated with infarct size, microvascular obstruction (MVO), left ventricular ejection fraction (LVEF) and clinical outcomes after primary percutaneous coronary intervention (PCI). METHODS Individual patient data from 1598 patients undergoing primary PCI in six randomized clinical tr...
Prolonged dual antiplatelet therapy is the treatment of choice for patients with an acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) with a drug-eluting stent.1,2...
#1Giulio G. Stefanini (Humanitas University)H-Index: 42
#2Carlo BriguoriH-Index: 61
Last. David CohenH-Index: 88
view all 30 authors...
Aims null The aim of this study was to assess the impact of chronic kidney disease (CKD) on the safety and efficacy of ticagrelor monotherapy among patients undergoing percutaneous coronary intervention (PCI). null Methods and results null In this prespecified subanalysis of the TWILIGHT trial, we evaluated the treatment effects of ticagrelor with or without aspirin according to renal function. The trial enrolled patients undergoing drug-eluting stent implantation who fulfilled at least one clin...
1 CitationsSource
#1Dominick J. Angiolillo (UF: University of Florida)H-Index: 106
#2D Cao (Mount Sinai Hospital)
Last. Timothy Collier (Lond: University of London)H-Index: 28
view all 29 authors...
Abstract null null Objectives null The aim of this study was to assess the impact of age on the safety and efficacy of ticagrelor monotherapy after percutaneous coronary intervention (PCI). null null null Background null As the risk for bleeding and ischemic complications after PCI increases with age, the authors conducted a pre-specified analysis of the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial to evaluate the possible benefits of ticagr...
#1Thomas J. Povsic (Duke University)H-Index: 35
#2Timothy D. HenryH-Index: 67
view all 11 authors...
Abstract null null Background null : Patients with refractory angina (RA) have poor quality of life and new therapies are needed. XC001 is a novel adenoviral vector expressing multiple isoforms of vascular endothelial growth factor (VEGF) promoting an enhanced local angiogenic effect. null null null Methods null : The null E picardial Delivery of null X C001 Gene Therapy for Refractory null A ngina null C oronary null T reatment (EXACT) trial is a 6-month (with 6-month extension) phase 1/2, firs...
#1Brian P O'Neill (HFH: Henry Ford Hospital)H-Index: 1
#2Cindy L. Grines (Cardiovascular Institute of the South)H-Index: 4
Last. Ehtisham Mahmud (UCSD: University of California, San Diego)H-Index: 31
view all 12 authors...
OBJECTIVES To compare in-hospital outcomes of bailout support to prophylactic support with percutaneous ventricular assist devices (pVAD) for high-risk nonemergent percutaneous coronary intervention (HRPCI). BACKGROUND Prophylactic support with pVAD for a HRPCI is used in patients felt to be at risk for hemodynamic collapse during PCI. An alternative strategy of bailout pVAD support in the event of hemodynamic collapse is also entertained. METHODS We compared the outcomes of patients entered in ...
#1E. Magnus Ohman (Duke University)H-Index: 135
#2Brittany A. Zwischenberger (Duke University)H-Index: 8
Last. Holger Thiele (Leipzig University)H-Index: 97
view all 3 authors...
#1Birgit Vogel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 16
#2Usman Baber (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 44
Last. Roxana Mehran (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 162
view all 29 authors...
Importance Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI). Objective To explore sex differences and evaluate the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin. Design, Setting, and Participants This was a prespecified secondary analysis of TWILIGHT, an investigator-initiated, placebo-contro...
1 CitationsSource